Search
Showing results for "preterm birth lungs"
A third of Western Australian one-year-olds and up to two thirds of three-year-olds have low iron, a study by The Kids Research Institute Australia has found.
A national campaign launched on Channel 7’s Telethon aims to build community understanding of the amazing untapped potential of a baby’s developing brain, through a remarkable animated creature.
The Kids Research Institute Australia and Perth Children’s Hospital clinician-researchers have found more than one in ten children across four remote Kimberley communities have protracted bacterial bronchitis.
The Kids Research Institute Australia researchers set out on a worldwide search to find out all they could about Rett syndrome, establishing databases and creating awareness.
Pulmonary exacerbations are associated with increased morbidity and mortality in people with cystic fibrosis (CF). There is no consensus about which outcomes should be evaluated in studies of pulmonary exacerbations or how these outcomes should be measured.
Wal-yan Respiratory Research Centre researchers will use almost $1.2 million in WA Child Research Fund grants to determine why Indigenous children develop bronchiectasis at such high rates after contracting bronchiolitis, and to test a promising novel treatment for respiratory syncytial virus (RSV).
A The Kids Research Institute Australia spin-off company has received $20 million from the Medical Research Commercialisation Fund to develop a promising new therapy for the treatment of Cystic Fibrosis.
Nontypeable Haemophilus influenzae (NTHi) is a major otitis media (OM) pathogen, with colonization a prerequisite for disease development. Most acute OM is in children <5 years old, with recurrent and chronic OM impacting hearing and learning. Therapies to prevent NTHi colonization and/or disease are needed, especially for young children. Respiratory viruses are implicated in driving the development of bacterial OM in children.
Perth researchers are leading an international clinical trial focused on preventing the spread of COVID-19 by testing the effectiveness of the drug interferon in reducing the infectiousness of people who contract the virus.
Patients battling antibiotic-resistant superbugs will soon have access to life-saving WA-made therapies that could help treat lung, skin and ear infections as well as bacterial infections like Golden Staph. Western Australia's inaugural phage manufacturing facility – spearheaded by a team at the